抱歉，此活动已过期，不再可用于CME信用。您可能仍然喜欢该计划。
CME信息
Provider Statement:This continuing medical education activity is provided by
.
Support Statement:这项活动得到了Regeneron Pharmaceuticals，Inc。的独立医学教育资助。
Target Audience:The intended audience for this activity isretina specialists and other health care professionals involved in the management of patients with retinal diseases.
学习目标：成功完成这项活动后，参与者应该更好地能够：
- Evaluate innovations in imaging that can result in earlier diagnosis, treatment, and monitoring of retinal diseases.
- Assess the evidence on safety and efficacy to optimize the use of conventional, new, and emerging intravitreal treatments for retinal diseases.
- Evaluate techniques and technology that advance the timing, dosing, selection, and transitioning of treatment for retinal diseases.
- 探索新兴疗法的新型作用机制，这些机制可能改善视网膜疾病患者的VA和结果。
- Explain how advances in the treatment of retinal diseases achieved in clinical trials can be applied to real world practice.
- 评估与注射方案有关的最新发现以及视网膜液体管理实践，这些方法可能会改善视网膜疾病治疗玻璃体内疗法的长期益处。
Chief Medical Editor:
Rishi P. Singh，医学博士
Cole Eye Institute的工作人员医师
Medical Director, Clinical Systems Office
克利夫兰诊所
眼科副教授
Case Western Reserve University
克利夫兰，哦
Faculty:
Sophie J. Bakri, MD
眼科教授
梅奥诊所
Rochester, MN
马克·R·巴拉卡特（Mark R. Barakat），医学博士
外科医生
亚利桑那州的视网膜顾问
Phoenix, AZ
Dilsher Dhoot, MD
玻璃体外科医生
加州再保险tina Consultants
加利福尼亚州圣塔芭芭拉
K. David Epley, MD
Children's Eye Care
Kirkland, WA
Carl D. Regillo, MD, FACS
Director, Wills Eye Retina Service
眼科教授
托马斯·杰斐逊大学
中大西洋视网膜
Philadelphia, PA
Reviewer:
Ronald A. Codario，医学博士，EMBA，FACP，FNLA，RPVI，CHCP
Accreditation:
维迪科医学教育获得了认证委员会的持续医学教育认可，以为医师提供继续医学教育。
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25AMA PRA类别1信用™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.
This enduring material is approved for 1 year from the date of original release, July 31, 2020, through July 30, 2021.
How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 7 out of 10 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue anAMA PRA类别1信用™证书。
披露：
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience therelevant financial relationshipsof the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
首席医学编辑和教师报告以下关系：
Rishi P. Singh，医学博士
咨询费：Alcon，Bausch + Lomb，Genentech，Novartis，Regeneron，Zeiss
Contracted Research:Aerie，Apellis，Graybug Vision
Sophie J. Bakri, MD
咨询费：Alimera, Allegro, Allergan, EyePoint, Genentech, Kala, Novartis, Oxurion, Roche
马克·R·巴拉卡特（Mark R. Barakat），医学博士
咨询费：Alimera，Allegro，Allergan，Bausch + Lomb，Clearside，Genentech，Novartis
演讲局：Genentech, Novartis
所有者权益：OHR，Oxurion
Travel Support:科迪亚克
Dilsher Dhoot, MD
咨询费：Alimera，Allergan，Eyepoint，Genentech，Novartis，Ocular Therapeutix，Regeneron，Santen
演讲局：Alimera, EyePoint, Genentech, Novartis, Regeneron
Contracted Research:Genentech, Regeneron
所有者权益：Vortex Surgical
K. David Epley, MD
咨询费：内瓦卡
Carl D. Regillo MD, FACS
咨询费：Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug Vision, Kodiak, Merck, Notal Vision, Novartis, Takeda
Contracted Research:Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug Vision, Kodiak, Notal Vision, Novartis, Regeneron, Regenxbio
Reviewer reports the following relationship(s):
Ronald A. Codario，医学博士，EMBA，FACP，FNLA，RPVI，CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
签署的披露在医学和合规办公室Vindico医学教育上备案。
Unlabeled and Investigational Usage:
建议听众，这种持续的医学教育活动可能包含对美国食品药品监督管理局（FDA）批准的产品或未经FDA未批准的产品的未标记用途的参考。教职员工已经意识到他们披露这种使用量的义务。如果任何讲话者/作者打算讨论非FDA批准或产品/设备的研究用途，所有活动参与者都将获悉。
Copyright Statement:
由NJ 08086-9447的Vindico Medical Education创建和出版。电话：856-994-9400;传真：856-384-6680。在美国印刷。版权所有©2020 Vindico医学教育。版权所有。未经出版商的书面许可，本出版物的任何部分都不能复制。在Vindico医学教育中或任何一项持续医学教育活动中提出的材料并不一定反映了Vindico医学教育的观点和观点。Vindico医学教育或教师都不认可或推荐任何技术，商业产品或制造商。教师/作者可以讨论尚未获得美国食品药品监督管理局尚未批准的材料和/或产品的使用。 All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
联系我们cme@vindicoCME.com